A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/138 (2006.01) A61K 31/00 (2006.01) A61K 31/135 (2006.01) A61K 31/40 (2006.01) A61P 9/14 (2006.01) C07K 14/71 (2006.01) C07K 16/22 (2006.01)
Patent
CA 2162586
TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are characterized by a reduced vessel lumen diameter. In a preferred embodiment of the invention, TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respell to disease states involving proliferation and/or migration of vascular smooth muscle cells over time. Further provided is a method for determining TGF-beta in vitro, thereby identifying a patient at risk for atherosclerosis and monitoring a recipient that has received one or more administrations of a TGF-beta activator or production stimulator.
Grainger David J.
Kemp Paul R.
Metcalfe James C.
Weissberg Peter L.
Goudreau Gage Dubuc
Neorx Corporation
Poniard Pharmaceuticals Inc.
LandOfFree
Prevention and treatment of pathologies associated with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of pathologies associated with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of pathologies associated with... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1802811